Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$1.04 -5.5%	$1.23	$0.66 ▼ $5.92	$119.18M	2.23	2.21 million shs	3.75 million shs
GLSI Greenwich LifeSciences	$8.99 +0.7%	$9.58	$8.06 ▼ $55.00	$120.20M	1.69	43,314 shs	83,487 shs
PLUR Pluri	$5.09 -0.2%	$4.80	$3.33 ▼ $7.13	$39.86M	0.77	20,170 shs	11,663 shs
VIGL Vigil Neuroscience	$7.95	$5.31	$1.31 ▼ $7.96	$371.03M	3.4	675,686 shs	303,955 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	0.00%	-12.61%	-15.79%	+31.63%	-68.29%
GLSI Greenwich LifeSciences	0.00%	+1.01%	-8.36%	-5.77%	-47.91%
PLUR Pluri	0.00%	+28.54%	+14.13%	+17.82%	-11.94%
VIGL Vigil Neuroscience	0.00%	+0.38%	+0.89%	+346.63%	+98.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FATE Fate Therapeutics	4.1328 of 5 stars	3.1	3.0	4.7	2.5	1.7	0.6
GLSI Greenwich LifeSciences	1.7433 of 5 stars	3.5	0.0	0.0	1.6	3.3	0.0
PLUR Pluri	2.9888 of 5 stars	3.5	5.0	0.0	2.6	1.7	0.0
VIGL Vigil Neuroscience	3.6376 of 5 stars	4.0	5.0	0.0	1.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.13	Hold	$3.83	268.59% Upside
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	333.82% Upside
PLUR Pluri	3.00	Buy	$12.00	135.76% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	35.85% Upside

Current Analyst Ratings Breakdown

Latest PLUR, VIGL, FATE, and GLSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/2/2025	PLUR Pluri	Industrial Alliance Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
6/2/2025	PLUR Pluri	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/28/2025	VIGL Vigil Neuroscience	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$11.00 ➝ $8.00
5/27/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$14.00 ➝ $8.00
5/23/2025	VIGL Vigil Neuroscience	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Neutral	$8.00
5/22/2025	VIGL Vigil Neuroscience	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$13.63M	8.74	N/A	N/A	$2.80 per share	0.37
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.19 per share	N/A
PLUR Pluri	$330K	120.77	N/A	N/A	$1.00 per share	5.09
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
GLSI Greenwich LifeSciences	-$15.79M	-$1.26	N/A	N/A	N/A	N/A	-450.87%	-333.18%	8/12/2025 (Estimated)
PLUR Pluri	-$20.89M	-$5.53	N/A	∞	N/A	-2,563.29%	-4,191.91%	-85.40%	9/16/2025 (Estimated)
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	8/12/2025 (Estimated)

Latest PLUR, VIGL, FATE, and GLSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/13/2025	Q3 2025	PLUR Pluri	N/A	-$0.94	N/A	-$0.94	N/A	$0.43 million
5/7/2025	Q1 2025	VIGL Vigil Neuroscience	-$0.53	-$0.49	+$0.04	-$0.49	N/A	N/A
4/15/2025	Q4 2024	GLSI Greenwich LifeSciences	-$0.21	-$0.61	-$0.40	-$0.61	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	8.81	8.81
GLSI Greenwich LifeSciences	N/A	1.91	1.91
PLUR Pluri	51.65	4.81	4.81
VIGL Vigil Neuroscience	N/A	2.97	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
GLSI Greenwich LifeSciences	4.16%
PLUR Pluri	16.59%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	5.51%
GLSI Greenwich LifeSciences	51.67%
PLUR Pluri	25.93%
VIGL Vigil Neuroscience	18.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
GLSI Greenwich LifeSciences	3	13.37 million	6.46 million	Not Optionable
PLUR Pluri	150	7.83 million	5.80 million	Optionable
VIGL Vigil Neuroscience	40	46.67 million	38.27 million	Not Optionable

PLUR, VIGL, FATE, and GLSI Headlines

Recent News About These Companies

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? - Nasdaq

June 27 at 4:25 AM | nasdaq.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?

June 25, 2025 | zacks.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $10.80 Consensus Price Target from Analysts

June 20, 2025 | americanbankingnews.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Consensus Rating of "Hold" from Analysts

June 17, 2025 | marketbeat.com

Two Sigma Investments LP Acquires 41,836 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 12, 2025 | marketbeat.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

June 9, 2025 | prnewswire.com

Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Squarepoint Ops LLC Acquires New Shares in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 9, 2025 | marketbeat.com

Millennium Management LLC Boosts Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 9, 2025 | marketbeat.com

Jane Street Group LLC Invests $83,000 in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 9, 2025 | marketbeat.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Holdings Lifted by Two Sigma Advisers LP

June 8, 2025 | marketbeat.com

Vigil Neuroscience halts Phase 2 trial for ALSP treatment

June 5, 2025 | investing.com

Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial

June 5, 2025 | biospace.comB

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...

June 5, 2025 | morningstar.comM

Disappointing results see Vigil Neuro drop iluzanebart development

June 4, 2025 | thepharmaletter.comT

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm

June 4, 2025 | prnewswire.com

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

June 4, 2025 | globenewswire.com

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

June 2, 2025 | zacks.com

HC Wainwright Has Bearish Forecast for VIGL FY2026 Earnings

May 30, 2025 | marketbeat.com

Stifel cuts Vigil Neuroscience stock rating, lowers target to $8

May 29, 2025 | investing.com

Stifel Downgrades Vigil Neuroscience (VIGL)

May 29, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock
By Leo Miller | June 9, 2025
View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock

PLUR, VIGL, FATE, and GLSI Company Descriptions

Fate Therapeutics NASDAQ:FATE

$1.04 -0.06 (-5.45%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.08 +0.04 (+3.85%)

As of 04:04 AM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Greenwich LifeSciences NASDAQ:GLSI

$8.99 +0.06 (+0.67%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.74 -0.25 (-2.73%)

As of 04:30 AM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Pluri NASDAQ:PLUR

$5.09 -0.01 (-0.20%)

Closing price 06/27/2025 03:58 PM Eastern

Extended Trading

$5.32 +0.23 (+4.52%)

As of 04:11 AM Eastern

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Vigil Neuroscience NASDAQ:VIGL

$7.95 0.00 (0.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.94 -0.01 (-0.13%)

As of 04:04 AM Eastern

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time